Too often, recruiters are more clear on what a position will “do” rather than what it will “achieve”.Outlining tasks and responsibilities takes priority over goals and impact.But to attract top talent, you need to define and explain what success looks…
HOME > COMMENTARY
COMMENTARY
- Current New Drug Development in the Japanese Pharmaceutical Industry(2)
February 11, 2008
- Current New Drug Development in the Japanese Pharmaceutical Industry(1)
February 11, 2008
- COMMENTARY/Generic Makers Increase Investment, but Will Consumption Really Increase as Gov't Hopes?
February 4, 2008
- COMMENTARY/Full-Scale M&As Imminent among Dispensing Pharmacy Chains
January 28, 2008
- OPINION/The East versus West Dilemma
January 28, 2008
- COMMENTARY/Full-Scale M&As Imminent among Dispensing Pharmacy Chains
January 28, 2008
- No More Need for MRs? -A Hell beyond the 2010 Crisis?-
January 14, 2008
- COMMENTARY/Year 2007 in Retrospect
December 24, 2007
- COMMENTARY/Appreciation Mixed with Concern: Proposed NHI Pricing Reform
December 17, 2007
- COMMENTARY/Fight over Medical Fee/NHI Price Revision Rates Begin
December 3, 2007
- COMMENTARY:Korosho Must Explain Its "Primary Doctor" System Proposal in Detail
October 1, 2007
- Gakkai, Specialty Certification and Industry by Mark Colby
September 10, 2007
- COMENTARY:Korosho Required to Cut \220 Bil. in Social Security Spending
September 3, 2007
- COMMENTARY/NHI Drug Pricing System Reform: Many Similarities in Proposals from JPMA, PhRMA, EFPIA
August 27, 2007
- COMMENTARY/Range of Drugs Re-priced due to Expansion of Market May Be Expanded
July 23, 2007
- COMMENTARY/Market for Osteoporosis Drugs Booms
July 9, 2007
- COMMENTARY/Pressure Mounting on Long-Listed Original Drugs
July 9, 2007
- COMMENTARY:Generic Firms Need Stronger Business Platform to Ensure Nationwide Stable Supply
June 25, 2007
- COMMENTARY/Provisional Deliveries without Agreement on Prices
June 11, 2007
- COMMENTARY/Show Road Map to the Goal - 30% Share for Generics
June 4, 2007
ページ
Pharmaceutical companies are giving high marks to Japan’s drug pricing reform for FY2024. According to a survey conducted by Jiho, 51% of all respondents expressed a positive opinion of the reform, saying that they were “somewhat satisfied” with it. The…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…